Acadia Pharmaceuticals vs Nasus Pharma
ACAD and NSRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACAD and NSRX compare
Acadia Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 30.1% compared with −0.47% at Nasus Pharma.
Acadia Pharmaceuticals scores higher on the StockData Score (17 against 6 for Nasus Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACAD | NSRX |
|---|---|---|
| Size and price | ||
| Market cap | $3.2B | – |
| Share price | $18.75 | $2.87 |
| Change, 1 year | −22.3% | −62.2% |
| Change, 5 years | −2.1% | – |
| Beta (5Y) | 0.78 | 1.33 |
| Employees | 798 | – |
| StockData Score | ||
| Total score | 17 (better) | 6 |
| Valuation score | 5 (better) | 0 |
| Growth score | 2 (better) | 0 |
| Performance score | 4 (better) | 1 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 8.9× | – |
| P/S | 2.7× | – |
| P/B | 2.3× | – |
| EV/EBITDA | 18.4× | – |
| P/FCF | 39.4× | – |
| FCF yield | 2.5% | – |
| Fair value | $31.63 | – |
| Margin of safety | 40.7% | – |
| Growth | ||
| Revenue growth (TTM) | 14.8% | – |
| Revenue growth, 5Y average | 19.4% | – |
| Net income growth (TTM) | 38.7% | – |
| EPS growth (TTM) | 35.5% | – |
| Profitability | ||
| Gross margin | 90.5% | – |
| Operating margin | 10.2% (better) | −0.40% |
| Net margin | 30.1% (better) | −0.47% |
| FCF margin | 6.8% (better) | −0.40% |
| Return on equity | 31.4% (better) | −175% |
| Return on invested capital | 50.8% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 3.82 | 8.77 (better) |
| Altman Z-score | 4.94 | – |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | −1.5% | – |
| Shareholder yield | −1.5% | – |
| Ownership | ||
| Held by institutions | 97.9% | 23.9% |
| Held by insiders | 27.8% | 59.3% |
| Insider net buying, 12 months | −$2.5M | $61.8K (better) |
| Short interest, % of float | 6.7% | 1.9% |
Go deeper
- ACAD stock overview
- ACAD income statement
- ACAD valuation and score
- NSRX stock overview
- NSRX income statement
- NSRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.